The role of miR-125b in T lymphocytes in the pathogenesis of systemic Lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 31, Issue 2, 2013, Pages 0263-0271

  Luo, Xiaofang ^a   Zhang, Limin ^b   Li, Mengtao ^a   Zhang, Wen ^a   Leng, Xiaomei ^a   Zhang, Fengchun ^a   Zhao, Yan ^a   Zeng, Xiaofeng ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

MicroRNA; MiR 125b; Systemic lupus erythematosus; Target gene

Indexed keywords

LUCIFERASE; MICRORNA; MICRORNA 125B; MICRORNA 26A; MICRORNA 326; STAT3 PROTEIN; TRANSCRIPTION FACTOR ETS 1; UNCLASSIFIED DRUG; ETS1 PROTEIN, HUMAN; MIRN125 MICRORNA, HUMAN; STAT3 PROTEIN, HUMAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ETS1 GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; STAT3 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION; 3' UNTRANSLATED REGION; CASE CONTROL STUDY; CELL STRAIN HEK293; DNA MICROARRAY; GENETIC MARKER; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY;

3' UNTRANSLATED REGIONS; CASE-CONTROL STUDIES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENES, REPORTER; GENETIC MARKERS; HEK293 CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEIN C-ETS-1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TRANSFECTION;

MLCS; MLOWN;

EID: 84875781381     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. RAHMAN A, ISENBERG DA: Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-39.
2. +CD25(high) T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-88.
3. SIDIROPOULOS PI, BOUMPAS DT: Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13: 391-7.
4. AMBROS V: The functions of animal micro- RNAs. Nature 2004; 431: 350-5.
5. AMBROS V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113: 673-6.
6. BARTEL DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
7. LEWIS BP, BURGE CB, BARTEL DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
8. LIM LP, LAU NC, GARRETT-ENGELE P et al.: Microarray analysis shows that some micro- RNAs downregulate large numbers of target mRNAs. Nature 2005; 433: 769-73.
9. KREK A, GRÜN D, POY MN et al.: Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
10. BALTIMORE D, BOLDIN MP, O'CONNELL RM, RAD DS, TAGANOV KD: MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9: 839-45.
11. LODISH HF, ZHOU B, LIU G, CHEN CZ: Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008; 8: 120-30.
12. STANCZYK J, PEDRIOLI DM, BRENTANO F et al.: Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008; 58: 1001-9.
13. OTAEGUI D, BARANZINI SE, ARMAÑANZAS R et al.: Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One 2009; 4: e6309.
14. DAI Y, HUANG YS, TANG M et al.: Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007; 16: 939-46.
15. TANG Y, LUO X, CUI H et al.: MicroRNA- 146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-75.
16. ZHAO X, TANG Y, QU B et al.: MicroRNA- 125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 3425-35.
17. ZHAO S, WANG Y, LIANG Y et al.: MicroRNA- 126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum 2011; 63: 1376-86.
18. STAGAKIS E, BERTSIAS G, VERGINIS P et al.: Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70: 1496-506.
19. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
20. + T cells by the microRNA miR-125b. Nat Immunol 2011; 12: 796-803.
21. TILI E, MICHAILLE JJ, CIMINO A et al.: Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179: 5082-9.
22. LE MT, TEH C, SHYH-CHANG N et al.: MicoRNA-125b is a novel negative regulator of p53. Genes Dev 2009; 23: 862-76.
23. BOUSQUET M, QUELEN C, ROSATI R et al.: Myeloid cell differentiation arrest by miR- 125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2:11) (p21:q23) translocation. J Exp Med 2008; 205: 2499-506.
24. SHI XB, XUE L, YANG J et al.: An androgenregulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci USA 2007; 104: 19983-8.
25. XIA HF, HE TZ, LIU CM et al.: MiR-125b expression affects the proliferation and apoptosis of human glioma cells by targeting Bmf. Cell Physiol Biochem 2009; 23: 347-58.
26. IORIO MV, FERRACIN M, LIU CG et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65: 7065-70.
27. SONKOLY E, WEI T, JANSON PC et al.: MicroRNAs: novel regulators involved in the pathogenesis of psoriasis. PLoS One 2007; 2: e610.
28. CRISPÍN JC, KYTTARIS VC, TERHORST C, TSOKOS GC: T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6: 317-25.
29. MUDD PA, TEAGUE BN, FARRIS AD: Regulatory T cells and systemic lupus erythematosus. Scand J Immunol 2006; 64: 211-8.
30. CRISPÍN JC, OUKKA M, BAYLISS G et al.: Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-6.
31. ZHOU Y, YUAN J, PAN Y et al.: T cell CD40LG gene expression and the production of IgG by autologous B cells in systemic lupus erythematosus. Clin Immunol 2009; 132: 362-70.
32. TOMITA N, MORISHITA R, TANIYAMA Y et al.: Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-7.
33. RANDI AM, SPERONE A, DRYDEN NH, BIRDSEY GM: Regulation of angiogenesis by ETS transcription factors. Biochem Soc Trans 2009; 37: 1248-53.
34. OETTGEN P: The role of ets factor in tumor angiogenesis. J Oncol 2010; 2010: 767384 Epub May 4 2010.
35. THOMAS RS, TYMMS MJ, MCKINLAY LH, SHANNON MF, SETH A, KOLA I: ETS1, NFkappaB and AP1 synergistically transactivate the human GM-CSF promoter. Oncogene 1997; 14: 2845-55.
36. MCKERCHER SR, TORBETT BE, ANDERSON KL et al.: Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J 1996; 15: 5647-58.
37. MCKINLAY LH, TYMMS MJ, THOMAS RS et al.: The role of Ets-1 in mast cell granulocyte- macrophage colony-stimulating factor expression and activation. J Immunol 1998; 161: 4098-105.
38. GRENNINGLOH R, KANG BY, HO IC: Ets-1, a functional cofactor of T-bet, is essential for Th1 inflammatory response. J Exp Med 2005; 201: 615-26.
39. HAN JW, ZHENG HF, CUI Y et al.: Genomewide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1234-7.
40. SULLIVAN KE, PILIERO LM, DHARIA T, GOLDMAN D, PETRI MA: 3ṕolymorphisms of ETS1 are associated with different clinical phenotypes in SLE. Hum Mutat 2000; 16: 49-53.
41. LEVY DE, DARNELL JE JR: Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-62.
42. SCHINDLER CW: Series introduction. JAKSTAT signaling in human disease. J Clin Invest 2002; 109: 1133-7.
43. PRAMANIK R, JØRGENSEN TN, XIN H, KOTZIN BL, CHOUBEY D: Interleukin-6 induces expression of Ifi202, an interferon-inducible candidate gene for lupus susceptibility. J Biol Chem 2004; 279: 16121-7.
44. HARADA T, KYTTARIS V, LI Y, JUANG YT, WANG Y, TSOKOS GC: Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 2007; 40: 1-8.